RELATLIMAB for Metastatic malignant melanoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 6 adverse event reports in the FDA FAERS database where RELATLIMAB was used for Metastatic malignant melanoma.
Most Reported Side Effects for RELATLIMAB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Pneumonia | 13 | 7.3% | 7 | 9 |
| Malignant neoplasm progression | 9 | 5.1% | 7 | 7 |
| Myocarditis | 8 | 4.5% | 1 | 6 |
| Hypotension | 7 | 4.0% | 0 | 7 |
| Meningitis aseptic | 7 | 4.0% | 0 | 7 |
| Pyrexia | 7 | 4.0% | 0 | 6 |
| Sepsis | 7 | 4.0% | 4 | 5 |
| Adrenal insufficiency | 6 | 3.4% | 0 | 6 |
| Drug ineffective | 6 | 3.4% | 0 | 2 |
| Hepatitis | 6 | 3.4% | 1 | 5 |
| Myositis | 6 | 3.4% | 1 | 5 |
| Pericardial effusion | 6 | 3.4% | 0 | 6 |
| Dyspnoea | 5 | 2.8% | 1 | 5 |
| Headache | 5 | 2.8% | 0 | 3 |
| Hyponatraemia | 5 | 2.8% | 0 | 5 |
Other Indications for RELATLIMAB
Malignant melanoma (69)
Non-small cell lung cancer (26)
Acute myeloid leukaemia (11)
Chordoma (8)
Glioblastoma multiforme (8)
Head and neck cancer (6)
Other Drugs Used for Metastatic malignant melanoma
NIVOLUMAB (4,628)
IPILIMUMAB (4,430)
DABRAFENIB (3,885)
PEMBROLIZUMAB (2,742)
TRAMETINIB DIMETHYL SULFOXIDE (2,031)
VEMURAFENIB (1,848)
TRAMETINIB (1,604)
COBIMETINIB (898)
ENCORAFENIB (865)
BINIMETINIB (841)